Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 07/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Novel Drug Delivery Systems In Cancer Therapy Market Projected To Boost On Account Of Rising Cases Of Cancer Till 2025: Grand View Research, Inc.

(July 12, 2018)


"Grand View Research, Inc. - Market Research And Consulting."
According to a report by Grand View Research, Inc., global novel drug delivery systems (NDDS) in cancer therapy market is anticipated to value USD 26.61 billion by 2025. Growing requirement for advanced medical devices to avail better treatment is anticipated to propel demand for novel drug delivery systems.

According to a report by Grand View Research, Inc., global novel drug delivery systems (NDDS) in cancer therapy market is anticipated to value USD 26.61 billion by 2025. Growing requirement for advanced medical devices to avail better treatment is anticipated to propel demand for novel drug delivery systems. These systems are likely to protect drugs essential for cancer treatment from enzymatic and chemical degradation.  

Growing need for cancer therapeutic drugs owing to rising cases of cancer is expected to influence growth of market. Spreading awareness among patients regarding availability of alternative methods of cancer treatments can stimulate market growth.  Rising cases of cancer owing to unhealthy lifestyle is anticipated to influence growth of market. Increasing R&D investments to expand product pipeline and for regulatory approvals of new products can influence market growth. Supportive reimbursement scenarios in developed nations coupled with availability of research funding is likely to augment market growth during the forecast period (2014 to 2025).  

Full Research Report On Novel Drug Delivery Systems (NDDS) In Cancer Therapy Market Analysis :

https://www.grandviewresearch.com/industry-analysis/novel-drug-delivery-systems-in-cancer-therapy

U.S. NDDS in cancer therapy market, by product, 2014 - 2025 (USD Billion)

The NNDS in cancer therapy market can be segregated on the basis of product and region. Based on product, the market can be categorized into embolization particles and nanoparticles. In 2016, nanoparticles segment dominated the market and accounted of largest market share. It is anticipated to grow at similar pace during the forecast period. These type of drug delivery systems are expected to encapsulate various drugs and protect them from enzymatic and chemical degradation. In addition, they can provide long circulation half-lives, improved pharmacokinetics and reduced side effects. Moreover, these systems can also offer enhanced permeability to allow efficient delivery of drugs to cancer tissues.

Based on aforementioned properties, nanoparticles can replace conventional chemotherapy treatment attributed to less risk to healthy tissues and high efficiency. Nanoparticles can be categorized into micelles, liposomes, polymers, and other nanoparticles. Micelles and liposomes are likely to be used for DNA delivery & targeting and can increase drug efficacy. In 2016, liposomes segment held for largest market share under nanoparticles segment. It is expected to grow at similar pace during the forecast period.   

View More Reports Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/medical-devices

NDDS in cancer therapy market, by region, 2016 (%)

On the contrary, embolization particles segment can be classified further into liquid emboli, PVA particles, drug eluting beads, and other embolization particles. These particles can be injected into small vessels providing blood to cancer cells. Such procedures can allow easy surgical reception of cancer cells resulting from reduced blood loss.  

Regional segmentation includes Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. In 2016, North America region dominated the market and accounted for 36.8% revenue share. Increasing number of research activities to develop new therapies can fuel growth of market in the region. In addition, growing awareness availability of novel drugs attributed to promotional and marketing activities of manufacturers is anticipated to propel market growth. Moreover, growing budget for novel drug discovery coupled with increasing number of food and drug administration (FDA) approvals can also fuel market growth in the region.

On the contrary, European market followed North America and stood second in terms of revenue share in 2016. It is expected to witness significant growth during the forecast period attributed to growing healthcare expenditure. High prevalence of cancer patients coupled with rise in research funding for cancer treatments can fuel market growth. Many local organizations in United Kingdom and Germany are expected to fund new technologies, which in turn can influence market growth in the region.

In Asia Pacific, the market is expected to grow at fastest rate during the forecast period. Rising cases of cancer in China and Japan owing to increasing geriatric population can stimulate market growth. In addition, increasing number of research activities coupled with growing awareness regarding availability of new cancer therapies can augment growth of market in the region.

Some of the leading companies offering NNDS in cancer therapy are Merrimack Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Limited; Johnson & Johnson Services, Inc.; Samyang Biopharmaceuticals Corporation; and Celgene Corporation. Geographic expansions, frequent product launches, and distribution agreements to increase customer base are likely to be key strategies players can undertake to expand their market share. In addition, companies are likely to invest in R&D activities to develop new and innovative NDDS systems in cancer therapy to expand their product portfolio.

Explore the BI enabled intuitive market research database, The Grand Library, by Grand View Research, Inc.

About Grand View Research


Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.
Email: [email protected]
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/novel-drug-delivery-systems-in-cancer-therapy



Source: www.abnewswire.com


Page: 1


Related Keywords:Business,Health & Medicine,Manufacturing & Industry,Pharmaceuticals & Biotech,Science,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference
  • Connected Health Devices: Global Market Forecast to 2023 - CAGR to Grow at 21.1%, Driven by the Increasing Adoption of IT in Healthcare

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines